ClinicalTrials.gg
CompletedNCT00751387Updated Nov 30, 2010

Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia

An observational study in Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 4 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-30.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Observational

Study type
Observational
Time perspective
Cross-sectional
Enrollment
559
Ages
18 Years and older
Sex
All
01

Study summary

The study is a cross sectional, epidemiology study of disease severity for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in four geographic regions in Australia (Illawarra, Sutherland, Hunter Urban and Hunter Rural).

02

Conditions studied

  • Ankylosing Spondylitis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
03

In context

Spondylitis, Ankylosing

507 studies on the registry are indexed under Spondylitis, Ankylosing; 91 are open to participants now.

This study's enrollment of 559 is above the median of 201 across 213 observational studies indexed under Spondylitis, Ankylosing.

Browse Spondylitis, Ankylosing studies →

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary care

Eligibility criteria

Inclusion criteria include:

Adult patients with a diagnosis of rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who have visited a primary care centre within one of the specified catchment areas for their condition within the last 24 months.

05

Study design

Time perspective
Cross-sectional
Enrollment
559 participants (actual)

Groups and cohorts

  • 1
06

What researchers measure

Primary outcomes

  1. Proportion of rheumatoid arthritis/psoriatic arthritis/ankylosing spondylitis patients in defined disease severity categories

    Time frame: Single visit

Secondary outcomes

  1. Proportion of patients exposed to biological disease modifying antirheumatic drugs

    Time frame: Single visit

07

Study locations

4 sites
  • Georgetown, 2298, Australia
  • Miranda, 2228, Australia
  • Newcastle, 2300, Australia
  • Wollongong, 2500, Australia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00751387
First posted
Sep 12, 2008
Start date
Nov 2008
Primary completion
Sep 2009
Completion
Sep 2009
Last update
Nov 30, 2010

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion